Drugs and Human Behavior - Couverture souple

Grilly, David M.

 
9780205318315: Drugs and Human Behavior

Synopsis

A valuable resource for any student majoring in the health sciences, Dr. Grilly's text examines human drug use from historical, societal, and biological perspectives.

This scholarly overview provides a rich foundation for understanding drugs and their usage. In addition to describing basic pharmacological principles, Grilly discusses the general factors behind and approaches for dealing with drug tolerance, dependence, and abuse. By using the most up-to-date research, and by presenting data in concise, jargon-free prose, the author has created one of the most comprehensive and accessible books on the subject.

Information is organized from the general to the specific, beginning with a historical perspective and subsequently moving through drug classifications, approaches to drug tolerance, dependence and abuse, psychological and behavioral effects, pharmacokinetics, mechanisms of action, common side effects, and current issues regarding drugs and their uses.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Biographie de l'auteur

Author #1:

After earning his doctorate in experimental psychology at the University of New Mexico in 1971, Dr. Grilly spent the next two years investigating the behavioral effects of cannabinoids after acute and chronic exposure in chimpanzees at Holloman Air Force Base in Alamogordo, New Mexico.  He then moved to Cleveland, Ohio, to take a position as a faculty member in the Psychology Department at Cleveland State University, where he spent the remainder of his 38 year career.  His research at CSU, primarily with rats, involved investigations of a variety of psychoactive drugs on a variety of behaviors.  These included investigating the potential use of signal detection theory in assessing  nociception and opiate withdrawal, determining the effects of drugs  on attentional processes (e.g., naltrexone, diprenorphine, morphine, barbiturates, amphetamine, cocaine, fluoxetine, nicotine, pemoline) and conditioned avoidance/escape behavior (e.g., clonidine, chlorpromazine, morphine), determining whether the effects of psychostimulants (e.g., cocaine, amphetamine) on sustained attention change with aging, and comparing the effects of very low to very high doses of amphetamine in rats with those shown in humans.  He also conducted research with humans investigating the effect of marijuana on visual short term memory and the changes in people’s perceptions of the effects of marijuana on driving. 


 

Author #2: Dr. John Salamone received his bachelor's degree from Rockhurst University in Kansas City, Missouri in 1978. He was a psychology major and biology minor.  Dr. Salamone then entered the psychobiology program at Emory University in Atlanta, Georgia, and graduated with a Ph.D. in 1982.  For postdoctoral training, Dr. Salamone received a National Science Foundation grant, and studied at Cambridge University in England. Dr. Salamone stayed in England for several more years, working at Merck, Sharpe and Dohme pharmaceutical laboratories. Upon returning to the United States, Dr. Salamone joined the Behavioral Neuroscience department at the University of Pittsburgh in 1986, and joined the Psychology Department at UConn in the fall of 1988. Dr. Salamone is now a Board of Trustees Distinguished Professor; he also is the chair of the Interdisciplinary Program in Neuroscience, and the head of the Behavioral Neuroscience Division of the Psychology Department. Dr. Salamone's research is largely in the fields of behavioral neuroscience and psychopharmacology, with an emphasis on studies related to Parkinson’s disease, depression, motivation, and effort-related decision making. Dr. Salamone has been the research advisor for more than 40 undergraduate honors students at the University of Connecticut. He was inducted as a member of the Connecticut Academy of Arts and Sciences in 2002, and he has received the University of Connecticut Alumni Association Award for Excellence in Teaching. His daughter, Isabella Salamone, is currently an honor student studying biology at the University of Pittsburgh. Dr. Salamone’s hobbies include travel, astronomy, book collecting and cooking.

Quatrième de couverture

By examining human drug use from historical, societal, and biological perspectives, Grilly: Drugs and Human Behavior, Fifth Edition, provides a rich foundation for understanding drugs affecting the brain. In addition to describing basic pharmacological principles, this text discusses the general factors behind drug tolerance, dependence, and abuse and approaches for dealing with these problems. Pharmacotherapy for the major mental disorders is described from both biochemical and clinical efficacy perspectives. By using the most up-to-date research, and by presenting data in concise, jargon-free prose, the author has created one of the most comprehensive and accessible books on the subject.

  • Incorporates the most up-to-date research to provide students with the most accurate information in the field, including a detailed discussion of new perspectives on the mechanisms behind antidepressant drugs and coverage of new FDA�??approved drugs used in the treatment of a variety of mental disorders.
  • Contains concise coverage of the most important aspects of a broad range of drugs that humans use to alter mood, mental function, and behavior.
  • Discusses a variety of mechanisms behind drug tolerance, dependence, and abuse phenomena, and links them together. Provides a number of approaches for prevention and for reduction of their consequences.
  • Describes the biochemical bases of action and the clinical efficacy of drugs commonly used in the treatment of mental and emotional disorders.
  • Describes new drug treatments and current trends in abuse and dependence. Includes an updated drug index at the end of the text.
  • Offers more coverage of potential pharmacotherapies for drug abuse and uses of opiates for controlling chronic pain.
  • Provides expanded coverage of benefits from the use of atypical antipsychotics as first-line treatments for schizophrenia, exposing alternative treatment options.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Autres éditions populaires du même titre